Dynamic imaging of individual remyelination profiles in multiple sclerosis - stroke?

Do we even know yet whether stroke causes demyelination? If so then this research is very important.
This is the only research on this I found in Google Scholar. Not very useful. And no protocols to recover from such damage.

 

Correlating magnetic resonance imaging markers of axonal injury and demyelination in motor impairment secondary to stroke and multiple sclerosis

 

http://www.ncbi.nlm.nih.gov/pubmed/26891452

Bodini B^1,2,3, Veronese M², García-Lorenzo D¹, Battaglini M⁴, Poirion E¹, Chardain A^3,5, Freeman L^1,3,6, Louapre C¹, Tchikviladze M⁶, Papeix C⁶, Dollé F³, Zalc B¹, Lubetzki C^1,6, Bottlaender M³, Turkheimer F², Stankoff B^1,3,5.

Author information

Abstract

BACKGROUND:

Quantitative in vivo imaging of myelin loss and repair in patients with multiple sclerosis (MS) is essential to understand the pathogenesis of the disease and to evaluate promyelinating therapies. Selectively binding myelin in the central nervous system white matter, [¹¹ C]PIB can be used as a positron emission tomography (PET) tracer to explore myelin dynamics in MS.

METHODS:

Patients with active relapsing-remitting MS (n=20) and healthy controls (n=8) were included in a longitudinal trial combining PET with [¹¹ C]PIB and magnetic resonance imaging. Voxel-wise maps of [¹¹ C]PIB distribution volume ratio, reflecting myelin content, were derived. Three dynamic indices were calculated for each patient: the global index of myelin content change; the index of demyelination; and the index of remyelination.

RESULTS:

At baseline, there was a progressive reduction in [¹¹ C]PIB binding from the normal-appearing white matter to MS lesions, reflecting a decline in myelin content. White matter lesions were characterized by a centripetal decrease in the tracer binding at the voxel level. During follow-up, high between-patient variability was found for all indices of myelin content change. Dynamic remyelination was inversely correlated with clinical disability (p=0.006 and beta-coefficient=-0.67 with the Expanded Disability Status Scale; p=0.003 and beta-coefficient=-0.68 with the MS Severity Scale), whereas no significant clinical correlation was found for the demyelination index.

CONCLUSIONS:

[¹¹ C]PIB PET allows quantification of myelin dynamics in MS and enables stratification of patients depending on their individual remyelination potential, which significantly correlates with clinical disability. This technique should be considered to assess novel promyelinating drugs. This article is protected by copyright. All rights reserved.
© 2016 American Neurological Association.